BioCentury | Jan 27, 2017
Clinical News

Tafoxiparin: Ph IIb started

...an adjunct to oxytocin for up to 36 hours in about 360 term-pregnant, nulliparous women. Dilafor AB...
...vaginal partus and proportion of women with cesarean sections Status: Phase IIb started Milestone: NA Chris Lieu DF01 Tafoxiparin Dilafor AB...
BioCentury | Oct 3, 2016
Financial News

Dilafor completes venture financing

Dilafor AB , Solna, Sweden Business: Genitourinary Date completed: 2016-09-27 Type: Venture financing Raised: SEK51 million ($5.9 million) Investors: Lee’s Healthcare Industry Investment Ltd.; Rosetta Capital Ltd.; Pila AB; Karolinska Development AB WIR Staff...
BioCentury | Jan 14, 2013
Finance

Rosetta's Nordic preferences

...cancer companies Akinion Pharmaceuticals AB , Aprea AB and Axelar AB ; women's health companies Dilafor AB...
...Axelar AB , Solna, Sweden Biosergen A/S , Trondheim, Norway Clanotech AB , Solna, Sweden Dilafor AB...
BioCentury | Dec 22, 2012
Financial News

Rosetta syndicate acquiring stake in Karolinska companies

...AB , Axelar AB , Dilaforette AB , NovaSAID AB, Inhalation Sciences Sweden AB , Dilafor AB...
BioCentury | Apr 4, 2011
Finance

Next Phase for Karolinksa

...prodrugs of already approved chemotherapeutic agents; wound healing play Pergamum AB ; and genitourinary company Dilafor AB...
BioCentury | Sep 20, 2010
Company News

Dilafor, Lee's Pharmaceutical deal

...patients who do not start labor spontaneously and are induced into labor. Under the deal, Dilafor...
...anticoagulation activity, has completed a Swedish Phase II trial to prevent protracted labor during childbirth. Dilafor AB...
BioCentury | Sep 14, 2009
Clinical News

Tafoxiparin: Phase II data

...and caesarean sections as a cause of protracted labor vs. placebo. Tafoxiparin was well tolerated. Dilafor AB...
Items per page:
1 - 7 of 7
BioCentury | Jan 27, 2017
Clinical News

Tafoxiparin: Ph IIb started

...an adjunct to oxytocin for up to 36 hours in about 360 term-pregnant, nulliparous women. Dilafor AB...
...vaginal partus and proportion of women with cesarean sections Status: Phase IIb started Milestone: NA Chris Lieu DF01 Tafoxiparin Dilafor AB...
BioCentury | Oct 3, 2016
Financial News

Dilafor completes venture financing

Dilafor AB , Solna, Sweden Business: Genitourinary Date completed: 2016-09-27 Type: Venture financing Raised: SEK51 million ($5.9 million) Investors: Lee’s Healthcare Industry Investment Ltd.; Rosetta Capital Ltd.; Pila AB; Karolinska Development AB WIR Staff...
BioCentury | Jan 14, 2013
Finance

Rosetta's Nordic preferences

...cancer companies Akinion Pharmaceuticals AB , Aprea AB and Axelar AB ; women's health companies Dilafor AB...
...Axelar AB , Solna, Sweden Biosergen A/S , Trondheim, Norway Clanotech AB , Solna, Sweden Dilafor AB...
BioCentury | Dec 22, 2012
Financial News

Rosetta syndicate acquiring stake in Karolinska companies

...AB , Axelar AB , Dilaforette AB , NovaSAID AB, Inhalation Sciences Sweden AB , Dilafor AB...
BioCentury | Apr 4, 2011
Finance

Next Phase for Karolinksa

...prodrugs of already approved chemotherapeutic agents; wound healing play Pergamum AB ; and genitourinary company Dilafor AB...
BioCentury | Sep 20, 2010
Company News

Dilafor, Lee's Pharmaceutical deal

...patients who do not start labor spontaneously and are induced into labor. Under the deal, Dilafor...
...anticoagulation activity, has completed a Swedish Phase II trial to prevent protracted labor during childbirth. Dilafor AB...
BioCentury | Sep 14, 2009
Clinical News

Tafoxiparin: Phase II data

...and caesarean sections as a cause of protracted labor vs. placebo. Tafoxiparin was well tolerated. Dilafor AB...
Items per page:
1 - 7 of 7